Uncover key drivers, emerging technologies, and competitive movements shaping the workstation graphics processing unit (gpu) market from 2026–2035 with trusted insights from The Business Research Company
What upper market value could the Uterine Fibroid Embolization Device Market reach by 2030 starting from 2026 levels?
The uterine fibroid embolization device market has experienced consistent expansion over recent years. This market is projected to grow from $5.93 billion in 2025 to $6.19 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 4.4%. The historical growth can be linked to factors such as the increasing prevalence of uterine fibroids among women of reproductive age, a rising number of gynecological procedures performed in hospital and clinic settings, the growing adoption of uterine artery embolization in interventional radiology, enhanced awareness of alternatives to open surgical myomectomy, and the broader implementation of minimally invasive treatment workflows in tertiary care centers.
The uterine fibroid embolization device market is anticipated to experience consistent expansion over the upcoming years. This market is projected to reach $7.33 billion in 2030, with a compound annual growth rate (CAGR) of 4.3%. The increase during the forecast period can be linked to several factors, including a heightened demand for uterus-sparing fibroid therapies among younger patients, a growing medical preference for less invasive and non-invasive treatment approaches, increased procedural adoption in ambulatory surgical centers, the expanded application of ablation and embolization devices for reducing fibroid size, and increased capital directed towards advanced delivery catheters and embolic systems to enhance treatment accuracy. Key trends anticipated in the same period involve the increasing embrace of minimally invasive embolization methods for uterine fibroid management, a stronger clinical inclination towards organ-preserving options instead of hysterectomy, greater deployment of image-guided interventional devices for targeted fibroid treatment, the broadened application of embolization procedures in outpatient and ambulatory surgical environments, and a rising need for precision delivery systems to enhance procedural safety and patient outcomes.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13551&type=smp
Which Drivers Are Influencing Long-Term Growth In The Uterine Fibroid Embolization Device Market?
The escalating need for minimally invasive surgical procedures is anticipated to fuel the expansion of the uterine fibroid embolization device market. Minimally invasive surgeries are surgical techniques that employ small incisions or the body’s natural openings to access and treat internal structures, organs, or tissues, thereby minimizing patient trauma. The preference for minimally invasive procedures is growing as both patients and healthcare providers seek treatments that reduce recovery times, lower complication risks, and enhance overall comfort. Uterine fibroid embolization devices are instrumental in these procedures, enabling precise and effective treatment of fibroids, which improves patient outcomes and procedural efficiency. For instance, in January 2025, according to AOS Open, a US-based medical journal, the rate of minimally invasive surgeries in hospitals with robotic-assisted systems has risen to 65.8% in 2025, up from 60.5% in 2022. Thus, the increasing demand for minimally invasive surgeries is a primary driver for the growth of the uterine fibroid embolization device market.
Which Segments Are Driving Activity In The Uterine Fibroid Embolization Device Market?
The uterine fibroid embolization device market covered in this report is segmented –
1) By Technology: Surgical Techniques, Laparoscopic Techniques, Ablation Techniques, Embolization Techniques
2) By Mode Of Treatment: Invasive Treatment, Minimally Invasive Treatment
3) By End User: Hospitals, Clinics, Ambulatory Surgical Center
Subsegments:
1) By Surgical Techniques: Open Surgery, Myomectomy
2) By Laparoscopic Techniques: Laparoscopic Myomectomy, Laparoscopic Hysterectomy
3) By Ablation Techniques: Radiofrequency Ablation, Microwave Ablation, Cryoablation
4) By Embolization Techniques: Transcatheter Arterial Embolization (TAE), Uterine Artery Embolization (UAE)
Which Trends Are Influencing The Performance And Direction Of The Uterine Fibroid Embolization Device Market?
Leading companies in the uterine fibroid embolization device market are developing innovative offerings, such as Minimally invasive fibroid management software, to improve the precision and efficiency of uterine fibroid treatment. Minimally invasive fibroid management software denotes a sophisticated digital platform created to assist clinicians with the planning, guidance, and execution of minimally invasive procedures for uterine fibroids, thereby enhancing procedural accuracy, safety, and overall patient results. For instance, in September 2024, Gynesonics, a US-based medical device company focused on minimally invasive gynecologic treatments, released SMART OS 2.4 software for its Sonata System to better manage uterine fibroids. SMART OS 2.4 upgrades the proprietary SMART Guide by reducing the minimum ablation zone size from 2.0 × 1.3 cm to 1.6 × 1.2 cm, cutting ablation volume by 38%, and optimizing the Thermal Safety Border for smaller fibroids. These advancements facilitate more precise, controlled treatments while protecting healthy uterine tissue, consequently improving both procedural efficiency and patient outcomes.
Which Major Firms Are Strengthening Their Position In The Uterine Fibroid Embolization Device Market?
Major companies operating in the uterine fibroid embolization device market are Johnson and Johnson Pvt Ltd., Medtronic plc., Boston Scientific Corporation, Olympus Corporation, Terumo Corporation, Ethicon Inc., Hologic Inc., CooperSurgical Inc., Cook Medical Inc., Karl Storz GmbH, Merit Medical Systems, CONMED Corporation, Lumenis Ltd., Richard Wolf GmbH, BTG International Ltd., Healthium MedTech Pvt. Ltd., Hironic Co.Ltd, Minerva Surgical Inc., Gynesonics Inc., Advanced Surgical Concepts PLLC
Access The Complete Report For Deeper Market Insights:
Which Global Regions Are Shaping The Competitive Landscape Of The Uterine Fibroid Embolization Device Market?
North America was the largest region in the uterine fibroid embolization device market in 2025. The regions covered in the uterine fibroid embolization device market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Uterine Fibroid Embolization Device Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=13551&type=smp
Browse Through More Reports Similar to the Global Uterine Fibroid Embolization Device Market 2026, By The Business Research Company
Uterine Fibroids Treatment Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/uterine-fibroids-treatment-global-market-report
Uterine Fibroids Treatment Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/uterine-fibroids-treatment-global-market-report
Tumor Embolization Devices Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/tumor-embolization-devices-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company